A Deep Dive Into the FDA's Psychedelic Clinical Research Guidelines

Decoding FDA Requirements

Watch as Altasciences’ panel of experts discuss the FDA’s recently published guidelines for early-phase clinical development of psychedelics and the assessment of abuse potential.

Topics covered:
      •   important FDA recommendations;
      •   clinical methods to optimize early-phase clinical trials with psychedelics;
      •   how to address the abuse potential evaluation requirement for psychedelic drugs; and
      •   strategies to ensure study integrity.

You may also be interested in the following resources:
      •   Webpage: CNS Drug Development Solutions
      •   Scientific Journal: Challenges Associated with Schedule I Therapeutic Development
      •   Webinar: Practical Approaches to Conducting Early Clinical Trials with Psychedelics

​​​​​